| Date | Title | Description |
| 01.09.2026 | Tagrisso + Orpathys improved PFS in 1L EGFRm lung | Tagrisso + Orpathys improved PFS in 1L EGFRm lung
Tue, Sep 01, 2026 08:00 CET Report this content
1 September 2026
Tagrisso plusOrpathysdemonstrated statistically significant and highly clinically meaningful improvement in progression-free ... |
| 01.09.2026 | AstraZeneca completes agreement for Zegfrovy | AstraZeneca completes agreement for Zegfrovy
Tue, Sep 01, 2026 08:05 CET Report this content
01 September 2026
AstraZeneca completes global license agreement
for oral EGFR inhibitor Zegfrovy for lung cancer
AstraZeneca today announced the s... |
| 17.08.2026 | Tagrisso+Orpathys improved PFS & OS in EGFRm lung | Tagrisso+Orpathys improved PFS & OS in EGFRm lung
Mon, Aug 17, 2026 08:00 CET Report this content
17 August 2026
Tagrisso plus Orpathys demonstrated statistically significant and clinically meaningful
improvements in progression-free an... |
| 17.08.2026 | Enhertu improved PFS in 1L HER2m lung cancer | Enhertu improved PFS in 1L HER2m lung cancer
Mon, Aug 17, 2026 08:30 CET Report this content
17 August 2026
Enhertu demonstrated statistically significant and clinically meaningful improvement in
progression-free survival as 1st-line treatm... |
| 15.07.2026 | AstraZeneca Licenses Zegfrovy From Dizal In Deal Worth Up To $1.5 Billion | AstraZeneca has entered into an exclusive global licensing agreement with Dizal Pharmaceutical for Zegfrovy, an oral targeted therapy approved in the U.S. and China for certain patients with non-small cell lung cancer.
Under the agreement, ... |
| 14.07.2026 | AstraZeneca licenses novel EGFR inhibitor | AstraZeneca licenses novel EGFR inhibitor
Tue, Jul 14, 2026 08:00 CET Report this content
14 July 2026
AstraZeneca enters exclusive global license agreement for novel oral
EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical
Co... |
| 06.06.2025 | A New Dawn in Cancer Treatment: Innovent and HUTCHMED's Breakthrough in Renal Cell Carcinoma | In the world of oncology, every breakthrough feels like a beacon of hope. Recently, Innovent Biologics and HUTCHMED announced a significant milestone: the acceptance of their New Drug Application (NDA) in China for a combination therapy tar... |
| 05.06.2025 | Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma | SAN FRANCISCO and SUZHOU, China, June 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 07.04.2025 | As Chinese Pharma Stocks Dive, Insiders Say Novel Drug Deals Remain Untouched by US Tariff Hike | (Yicai) April 7 -- The sharp selloff in Chinese pharmaceutical stocks was mainly due to market panic after the US jacked up the import tax on Chinese goods by more than expected, according to industry sources, who pointed out that innovativ... |
| 21.03.2025 | HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma | — First and only EZH2 inhibitor approved by the NMPA —
— HUTCHMED’s fourth product, and its first approval in hematological malignancies —
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Li... |
| 21.03.2025 | HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma | — First and only EZH2 inhibitor approved by the NMPA —
— HUTCHMED’s fourth product, and its first approval in hematological malignancies —
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Li... |
| 20.03.2025 | Intended Retirement of Independent Non-executive Directors and changes of composition of board committees | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Paul Rutherford Carter and Mr Graeme Allan Jack, wh... |
| 19.03.2025 | Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China | SAN FRANCISCO and SUZHOU, China, March 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 19.03.2025 | HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 | — SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance in the advanced ... |
| 18.03.2025 | HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), today jointly announce that the FRU... |
| 05.03.2025 | HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Ind... |
| 19.02.2025 | HUTCHMED to Announce 2024 Final Results | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March ... |
| 14.01.2025 | HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC | — Indication expands to include treatment-naïve patients —
— The 2021 conditional approval in previously treated patients converted to full approval —
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED... |
| 13.01.2025 | HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC | — Indication expands to include treatment-naïve patients —
— The 2021 conditional approval in previously treated patients converted to full approval —
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED... |
| 02.01.2025 | HUTCHMED's Strategic Shift: A $608 Million Move Towards Innovation | In a bold maneuver, HUTCHMED (China) Limited has announced the divestment of its 45% stake in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for approximately $608 million. This decision is not just a financial transaction; it represents... |
| 02.01.2025 | HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhib... | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolit... |
| 01.01.2025 | HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture | — HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally —
— Divestment proceeds to advance HUTCHMED’s pipeline and core innovati... |
| 01.01.2025 | HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture | — HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally —
— Divestment proceeds to advance HUTCHMED’s pipeline and core innovati... |
| 01.01.2025 | HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhib... | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolit... |
| 12.12.2024 | HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) | — US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe —
— Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal canc... |
| 11.12.2024 | HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Admini... |
| 07.12.2024 | Fosun International: A Beacon of ESG Excellence Amidst Global Challenges | In a world where corporate responsibility often feels like a buzzword, Fosun International Limited stands out like a lighthouse in a storm. Recently, the Hong Kong-based conglomerate secured five prestigious Environmental, Social, and Gover... |
| 06.12.2024 | Fosun International Garners Five ESG Awards from Two Global Media | HONG KONG, Dec. 6, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656) recently garnered five prestigious international Environmental, Social, and Governance (ESG) awards from two global media outlets, reflecting the m... |
| 04.12.2024 | Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer | SAN FRANCISCO, U.S. and SUZHOU, China, Dec. 4, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 03.12.2024 | HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer | — First regulatory approval for fruquintinib combination therapy with an immune checkpoint inhibitor —
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ... |
| 28.11.2024 | HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal with the China National Healthcare Securi... |
| 28.11.2024 | HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal with the China National Healthcare Securi... |
| 22.11.2024 | HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan | — Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 —
— Milestone payment to be made to HUTCHMED from Takeda —
— Fruquintinib already launched in several regions including the United States, Europe... |
| 21.11.2024 | HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan | — Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 —
— Milestone payment to be made to HUTCHMED from Takeda —
— Fruquintinib already launched in several regions including the United States, Europe... |
| 05.11.2024 | HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress | HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well ... |
| 31.10.2024 | HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a US$20 million milestone payment from its partner Taked... |
| 26.09.2024 | Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing | Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presen... |
| 30.08.2024 | HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA... |
| 30.08.2024 | HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA... |
| 21.08.2024 | HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a physician expert call with a professor and key opinion lead... |
| 31.07.2024 | HUTCHMED Reports 2024 Interim Results and Provides Business Updates | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:HCM; HKEX:13) today reports its financial results for the six months ended June 30, ... |
| 04.07.2024 | HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of a... |
| 24.06.2024 | Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a R&D update in Shanghai, China, and via webcast on Tuesd... |
| 21.06.2024 | HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda | — Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial —
— FRUZAQLA® (fruquintinib) is the first novel targeted therapy in the EU for metastatic colorectal cancer rega... |
| 21.06.2024 | HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda | — Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial —
— FRUZAQLA® (fruquintinib) is the first novel targeted therapy in the EU for metastatic colorectal cancer rega... |
| 16.06.2024 | HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology | — Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo —
— Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior lines of therapies or prior TPO/TPO-RA1... |
| 07.06.2024 | HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in... |
| 27.05.2024 | Dato-DXd improved OS in nonsquamous lung cancer | Dato-DXd improved OS in nonsquamous lung cancer
Mon, May 27, 2024 08:00 CET Report this content
This announcement contains inside information
27 May 2024
Datopotamab deruxtecan showed clinically meaningful overall survival
improvement vs. c... |
| 24.05.2024 | HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting | HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by... |
| 17.05.2024 | HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress | HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib,... |
| 17.05.2024 | HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces:-
(a) the retirement of Mr Simon To from the position as Chai... |
| 26.04.2024 | HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda | — If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade —
— Positive opinion based on results from FRESCO-2 Phase III clinic... |
| 05.04.2024 | Imfinzi improved OS & PFS in limited-stage SCLC | Imfinzi improved OS & PFS in limited-stage SCLC
Fri, Apr 05, 2024 08:00 CET Report this content
05 April 2024
Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung ... |
| 02.04.2024 | Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status | ROCKVILLE, Md. and SUZHOU, China, April 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 07.02.2024 | HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session | HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that data from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in ... |
| 02.02.2024 | Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED | Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor
I... |
| 01.12.2023 | HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses | HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Nov. 30, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today highlights that new clinical data from several ongoing studies with HUTCHMED inv... |
| 09.08.2022 | Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-004 | SAN DIEGO, SHANGHAI and HONG KONG, Aug. 9, 2022 /PRNewswire/ -- Inmagene Biopharmaceutical ("Inmagene") and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announce today that the first participant, based... |
| 06.07.2022 | Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007 | SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announces today that the first participant, ba... |
| 21.09.2021 | China's biotech industry has quietly surged to a $180 billion behemoth. Here's how it's reshaping biotech as we know it, from M&A to drug pricing | Employees at a pharmaceutical workshop in Haikou, Hainan Province of China. Photo by Yuan Chen/VCG via Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
China's biot... |
| 21.06.2021 | HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors | HONG KONG, June 21, 2021 /PRNewswire/ -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM) today announces that surufatinib has been granted approval for drug registration by the National Medical Products Administration of C... |
| 07.06.2021 | Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021 | SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for th... |
| 20.05.2021 | HUTCHMED (CHINA) LIMITED
HUTCHMED China : Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program (Form 6-K) | HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program
- HUTCHMED will review these highlights as part of its company update audio call and webcast on Wednesday, May 26 at 9 a.m. EDT to discuss d... |
| 09.04.2021 | HK-based buyout firm Baring to invest $100m in Chinese drug maker Hutchmed | Hong Kong-based buyout firm Baring Private Equity Asia has agreed to purchase $100 million worth of shares in Hutchison China MediTech (Hutchmed), a US- and London-listed, commercial-stage, biopharmaceutical firm that aims to treat cancer a... |
